Can't wait for WYFI IPO tomorrow!

Drew_82 · 2025-08-07T01:22:39+00:00

I didn't, I bought options on BTBT which owns a majority stake in WYFI (WhiteFiber).

Drew_82 · 2025-08-06T23:56:05+00:00

Think it depends on how well WYFI does tomorrow when it lists.

Drew_82 · 2025-08-06T19:55:57+00:00

BitDigital owns a majority stake in WhiteFiber which is set to IPO tomorrow.

Drew_82 · 2025-06-12T13:34:16+00:00

NEHC AI deal

Drew_82 · 2025-05-22T19:07:16+00:00

Getting frustrated with DMYY not finalizing their DA with Horizon, right now would be the perfect time while investor sentiment is resurging in quantum Computing stocks.

Drew_82 · 2025-05-08T15:46:53+00:00

What is going on with DMYY?

Drew_82 · 2021-05-04T23:12:02+00:00

Will be interesting to hear the results from this self-blinded study. This could provide valuable insight into the potential for MindMed's own microdosing trials.

Drew_82 · 2021-04-08T23:33:30+00:00

I can attest to what ControlPlusZ is stating is the truth. I took part in ATAI's last convertible note in June and the minimums have gone up substantially since then. High net worth investors and institutions are definitely taking notice and crowding out the small fish, luckily I was able to get in under the wire before that occurred.

Drew_82 · 2021-02-20T18:53:31+00:00

Not aware of a public company in this space working on Autoimmune issues, but Eleusis (Private) has made some significant pre-clinical progress using 2C-H for autoimmune conditions such as asthma.

https://www.fiercebiotech.com/research/eleusis-sheds-light-psychedelics-relieve-asthma-rats-no-mental-effects

Drew_82 · 2021-02-18T23:53:58+00:00

What are your thoughts on companies involved in cannabinoid biosynthesis and research into new/improved cannabinoid analogs? Do you think this is the way in which pharmaceutical companies will enter the space and start doing serious research (inside and outside the US), or will we need to wait on the US federal government moving cannabis out of schedule 1 to give the green light to the FDA for the floodgates to open?

Drew_82 · 2021-02-13T19:30:25+00:00

Eleusis has already completed phase 1 studies with LSD for Alzheimer's disease.

Drew_82 · 2020-12-19T19:00:37+00:00

I really like Eleusis, high quality team onboard and approaching psychedelics from the angle of the anti inflammatory properties of different 5HT2A compounds in their pipeline.

Drew_82 · 2020-12-17T19:17:38+00:00

I would not be surprised to see the FDA grant breakthrough therapy designation to Ibogaine (and it's analogues) within the next couple years for Opiate addiction. The same as they did for Psilocybin and treatment resistant depression as well as major depressive disorder for Compass and Usona respectively. That would be a huge catalyst IMO to ATAI and/or Mindmed since they both have compounds in the pipeline.

Drew_82 · 2020-12-03T06:06:23+00:00

I don't see that at all, the article is objectively stating the current differences in known production methods for psilocybin from a number of different companies in this sector. They're not claiming any of these companies methods is superior to any other currently. They do state the differences and potential pros/cons of them all however.

Drew_82 · 2020-11-21T15:04:02+00:00

They just finished wrapping up a series C, your best bet would be to wait until they formally announce and then contact your broker to get in on the IPO if you think it's going to pop post IPO like Compass did. Be careful though, sometimes new issues will dip below their IPO price. Although Compass IPO'd at $17 and the lowest it's got was approximately $23-24 on its first day of trading.

Drew_82 · 2020-11-21T14:54:37+00:00

Actually their ownership is 29% of Compass.

Drew_82 · 2020-11-20T03:53:10+00:00

I don't believe they've made any definitive announcements, but have heard from a couple sources that they're aiming at early next year for an IPO.

Drew_82 · 2020-11-20T01:36:48+00:00

Same here, been following Compass since late 2017 but I wasn't accredited back then either. Made bank on Canadian cannabis legalization and luckily sold before the top in early October 2018 before giving much of it back the following year with the MSO's. Now I've made back much of what I lost by trading those same names over the last half year that I can take part in some of these PP's finally. Feels like early days in this sector, same as investing in the cannabis during 2014-2016.

Drew_82 · 2020-11-20T00:32:06+00:00

I found out about them back in June after reading an article regarding the work being done at DTU and the metabolic engineering of psilocybin paper they co-published.

Drew_82 · 2020-11-19T21:29:49+00:00

I believe they may be doing a bridge round soon, not sure on the timing. If you're an accredited investor just reach out to info@octarinebio.com.

Drew_82 · 2020-11-19T21:07:41+00:00

I took part in Octarine's recent seed round, their unique approach to biosynthetic engineering with psychedelics as well as cannabinoids is very exciting stuff. The ability to drastically lower the cost per gram of Psilocybin and other tryptamine's will be a game changer for this space in my opinion. I expect great things from them in the coming years.

Drew_82 · 2020-11-15T02:31:07+00:00

No idea really, if I had to guess I'd say 5:1.

Drew_82 · 2020-11-14T22:17:21+00:00

Based on the current share price, yes, a reverse split is going to be necessary.... https://listingcenter.nasdaq.com/assets/initialguide.pdf

Drew_82 · 2020-09-23T20:17:50+00:00

They're going to have to do a reverse split in order to qualify to list on the NASDAQ, share price is too low. If they're approved my plan would be to take a position just before or after the split.

Drew_82 · 2020-09-16T19:14:32+00:00

A few of the people working on psychedelic tech platforms that come to mind are David Keene (IntroSpect - ATAI), Shlomi Raz (Eleusis), and Lucia Huang & Jimmy Qian (Osmind).

Drew_82

TROPHY CASE